Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) (the "Company" or "Cadrenal"), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to provide safer and ...

The company's latest presentation supports the idea that its lead program will make billions.

Patients have told ABC NEWS they're concerned about a lack of informed consent over Australia's most common osteoporosis drug ...

For the nine months ended September 30, 2024, LifeStance provided $44.9 million cash flow from operations, including $22.7 million during the third quarter of 2024. The Company ended the third quarter ...

(NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today announced financial ...

Just knowing that he had no consequence while my life felt like it was falling apart was a really difficult thing to manage ...

PACS Group stock has dropped nearly 33% since Monday following a scathing report from a forensic financial firm that accused ...

(Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS ... Nasdaq Delisting and Subsequent ...

Good day, everyone, and welcome to the Syndax Third Quarter 2024 Earnings Conference Call. Today's call is being recorded. All participants have been placed in a listen-only mode. You'll have an ...

Q4 2024 Earnings Conference Call November 5, 2024 4:00 AM ETCompany ParticipantsBritt Meelby Jensen - Chief Executive ...